RE:Lessons learned:Hummmm,,,,,were we not told our business model was to make deals which would capitalize the 001 trial,,,,,and then it was ,,make deals and to partner on 001?,,,,,, if you are not capable of making deals to the extent required,,step down and pass the tourch on,,,,,!
Where did the money go that lead to the amount of debt incurred?
Were we in the lab? What doing?,,,In others labs?? Our consultants,,,and business advisors and project manager,,,finacial officer and all,,,,,what had they accomplished these past 4 years in their respective chairs.....let me see,,,,,,,,little to nothing,,,,,or even less! Certainly nothing that lead to value added advancement. Just the very opposite! ,,the debt incurred seems to have only fattened the bank accounts of our leadership team.
Why was the Canadian Pl option not discussed?,,,,what was the difference in costs,,,,,if the FDA was too expensive and not going to play with us,,,were we not going to ever do a Pl on 001? What would the dilution in this scenario which would prove our technolgy was real.
We shareholders have been asleep at the wheel while out management team snoozed in the back me thinks,,,no,,not me thinks,,me knows by what is left to assess here!